Klaria Pharma Holding AB (publ.) (STO:KLAR)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.9840
+0.0040 (0.41%)
May 6, 2025, 4:54 PM CET
208.46%
Market Cap 142.44M
Revenue (ttm) 2.25M
Net Income (ttm) -47.75M
Shares Out 144.76M
EPS (ttm) -0.38
PE Ratio n/a
Forward PE 9.84
Dividend n/a
Ex-Dividend Date n/a
Volume 347,612
Average Volume 400,524
Open 0.9280
Previous Close 0.9800
Day's Range 0.9200 - 0.9940
52-Week Range 0.2500 - 1.8100
Beta 1.35
RSI 38.18
Earnings Date May 13, 2025

About STO:KLAR

Klaria Pharma Holding AB (publ.) operates as a pharmaceutical company. It develops Sumatriptan for the treatment of migraine. The company also develops Epinephrine/Adrenaline, which is in Phase I clinical trial for the treatment of acute allergic reaction. In addition, its pre-clinical product is Sirolimus for prevention of organ transplant rejection. Further, the company focuses on the commercialization of cannabis/cannabinoids. Klaria Pharma Holding AB (publ.) was incorporated in 2014 and is headquatered in Uppsala, Sweden. [Read more]

Sector Healthcare
Founded 2014
Employees 4
Stock Exchange Nasdaq Stockholm
Ticker Symbol KLAR
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.